Research on the Treatment of Severe Community-acquired Pneumonia in Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-10

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The need for glucocorticoid therapy in children with severe community-acquired pneumonia in the acute phase of the disease remains unclear. The implementation of this study could provide strong evidence on the need for adjuvant glucose therapy in children with severe community-acquired pneumonia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Glucocorticoids and Pulmonary Hypertension

NCT04499196

Pulmonary Hypertension Due to Lung Diseases and Hypoxia Pulmonary Hypertension Bronchopulmonary Dysplasia

UNKNOWN

A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia

NCT04041791

Pneumonia

COMPLETED PHASE3

Glucocorticoid Therapy Impact on the Inflammatory Response and Clinical Evolution in Patients With Severe Bronchiolitis

NCT02571517

Bronchiolitis, Viral

COMPLETED PHASE4

Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children

NCT00494624

Wheezing

UNKNOWN PHASE4

Severe Pneumonia In Children (S-PIC) Study: A Comparative Effectiveness Study Of Children With Severe Pneumonia In Asia

NCT04265287

Pneumonia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The use of glucocorticoid for severe community-acquired pneumonia in children is still controversial in clinic. There is still a lack of high quality clinical research results in this field. That's the purpose of this study. The study used oral glucocorticoids and placebos. It was a multicenter clinical study involving 160 people. The enrolled subjects were treated for 5 days after basic assessment, and the use of experimental drugs and changes in clinical manifestations and laboratory examination were strictly recorded. The possible adverse hormonal reactions such as hyperglycemia, hypertension and gastrointestinal ulcer bleeding should be closely monitored and appropriate treatment measures should be taken in time. Subject will be allowed to terminate the test if necessary. Record and discuss similar events. The double blind principle is strictly observed during the experiment to ensure the authenticity and reliability of the experimental data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

Prednisolone, oral, 2 mg/kg.d (maximum dose 60 mg/day), two or three times a day , 5 days.

Group Type EXPERIMENTAL

Prednisolone Acetate

Intervention Type DRUG

The experimental group took prednisolone acetate which is a kind of oral glucocorticoid.

Placebo group

The same amount of placebo was taken orally as the trial for 5 days

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

A placebo consistent in appearance with the prednisolone acetate.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prednisolone Acetate

The experimental group took prednisolone acetate which is a kind of oral glucocorticoid.

Intervention Type DRUG

placebo

A placebo consistent in appearance with the prednisolone acetate.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prednisolone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 1 month-\< 18 years old.
2. Clinical diagnosis of community-acquired pneumonia (fever, cough, sputum, chest pain, dyspnea, abnormal breath sounds in the lungs, imaging pneumonia changes).
3. Meet any of the following:

* (1) the general condition is very poor;
* (2) refusal to eat or dehydration;
* (3) Significantly increased respiratory rate (70 times/min \> infants, 50 times/min for older children\>);
* (4) dyspnea (three concave sign, moaning, nasal flapping)
* (5) hypoxemia (cyanosis, transcutaneous oxygen saturation\< 92% (not oxygenated));
* (6) Pulmonary infiltration≥ 2/3 lung or multilobar infiltration;
* (7) There is a pleural effusion;
* (8) Extrapulmonary complications

Exclusion Criteria

1. Systemic corticosteroids have been used to treat pneumonia before admission.
2. Use systemic glucocorticoids within 3 months before admission.
3. Hospital-acquired pneumonia.
4. Children with history of tuberculosis, branch expansion, tumors, immune deficiency, congenital heart, chronic pulmonary heart disease, kidney disease, severe malnutrition, recurrent respiratory infections, congenital bronchopulmonary dysplasia (BPD) and other underlying diseases.
5. Unconscious, need endotracheal intubation, children admitted to ICU.
6. Those who are allergic to the drugs or their preparation components involved in the study.
7. Those with hormonal contraindications: hypertension, diabetes, active peptic ulcer, adrenal hyperfunction, corneal ulcer, increased intraocular pressure, severe psychosis.
8. There is a current infection that is difficult to control with antibacterial drugs.
9. Children who are participating in other clinical trials.
10. The investigator believes that it is not suitable to participate in the study.

Minimum Eligible Age

1 Month

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No